Organ-on-chip Networking in Europe Joining forces for the future
Janny van den Eijnden – van Raaij Managing director hDMT EMA workshop Organ-on-Chip London 5 October 2017
Topics to be addressed •
hDMT Organ-on-Chip Consortium
•
European Organ-on-Chip network
•
Future EU funding opportunities
•
EU ORCHID project
hDMT’s dream Imagine: organ-on-chip models that mimic any part of the human body, to study human sickness and health, for personalized disease treatment or even prevention – available and affordable for everyone.
Towards an Organ-on-Chip Institute • Organ-on-chip on Dutch scientific agenda in 2011
Regenerative Medicine Personalised Medicine Brain, recognition and behavior
• Royal Netherlands Academy of Arts and Sciences Beyond Borders program (2011-2013) • Dutch Technology Consortium in 2012 • International Lorentz conference Leiden in 2012 • Bottom-up development of new technologybased institute (2013-2014) • hDMT Foundation in February 2015 • hDMT Consortium in September 2015
Human organ and disease models • Brain-on-chip • Cancer-on-chip • Heart-on-chip • Vessels-on-chip • Gut-on-Chip • Skin-on-Chip • Other Organ-on-chip technology platforms
Microfluidics Microelectronics Microfabrication Polymer chemistry Computational modeling Metabolism Food toxicology Drug development expertise Validation/valorization
Organ-on-chip Consortium Since 2015
Organization • Not for profit precompetitive technology institute • hDMT Foundation + 14 partners, hDMT Partner Agreement • Public-private partnership, multiple locations • Unique integration of multidisciplinary expertise, technologies and facilities • Open access publication • Clinical Advisory Board, Patient Advocacy group (to be established) • Collaboration with world-wide scientific research organizations (Europe, USA (Wyss)) • Towards a Center of Excellence on human organ and disease models-onchip
Role of hDMT Lobby/Image building
Project Management (Coordination and Monitoring)
Support (Grants, funding)
Collaboration Network formation
hDMT Central Coordinator
Facilitation
Platform function Communication Bundling and exchanging expertise and facilities
hDMT Organ-on-chip Consortium COMPANY NETWORK hDMT Foundation Target companies
Application needs
hDMT partners
Develop model
Build prototype
VALORIZATION
Specialized suppliers
Validate model
Manufacturing companies
Industrialize
Funding and networking NWO (Dutch Government) Netherlands organ-on-Chip Initiative (NOCI) 18.8 M, 10 yr (start 1 Oct 2017)
European Union
H2020 EU programs 2018-2020 FET-PROACTIVE FET-FLAGSHIP MARIE SKLODOWSKA-CURIE Action (ITN) NMBP call DT-NMBP-23-2020 (Next generation organ-on-chip (RIA))
European organ-on-chip network Organ-on-chip in Europe Austria (University of Technology Graz, Vienna) Belgium (IMEC) France (CEA-LETI) Germany (Fraunhofer, UMC Hamburg, Tissuse Berlin) Greece (Nat. Techn University of Athens) Italy (IMM-CNR) Luxembourg (University) Portugal (University of Coimbra) Spain (University of Zaragoza) Sweden (Uppsala University) Switzerland (EPFL) The Netherlands (hDMT) and more partners to come………………
ORCHID (ORgan-on-CHip In Development) H2020 Future and Emerging Technologies (FET) program CSA Coordination and support action Goal: • Create a roadmap for organ-on-chip technology • Build a network of academia, research institutes, industry, regulatory bodies, patient organizations etc. • Raise awareness by dissemination and communication
ORCHID objectives 1. Evaluation of the technology (state-of-the-art and unmet needs) 2. Identification of ethical issues, establishing standards and identifying measures for regulatory implementation 3. Analysis of economic and societal impact, training and education 4. Developing a roadmap which will guide the required R&D efforts 5. Raising awareness and building the ecosystem for organ-on-chip technology through a digital reference platform
Organ-on-chip Networking in Europe - European Medicines Agency
Oct 5, 2017 - Dutch Technology Consortium in 2012. ⢠International Lorentz conference Leiden in 2012. ⢠Bottom-up development of new technology- based institute ... Facilitation. Communication. Network formation. hDMT. Project Management. (Coordination and. Monitoring). Collaboration. Lobby/Image building ...
Apr 28, 2017 - 2. The United Kingdom will then become a 'third country'. 3. Preparing for the withdrawal is therefore not just a matter for EU and national authorities, but also for private parties. In view of the considerable uncertainties, in parti
May 30, 2017 - Pharmaceutical companies are invited to present their pre-clinical data pertaining to ... patients per year, as many questions about the best use of ALK ... of knowledge and evidence to support the planning and regulatory.
Aug 2, 2017 - ... EudraVigilance system to the new one, a 10 business day downtime is re- quired ... tions have now been added for initial testing of software/system .... qualified persons for pharmacovigilance (QPPVs) and companies' man-.
Mar 8, 2018 - Treatment of uterine fibroids. Haematology. New medicines authorised. ⢠Adynovi (rurioctocog alfa pegol). Treatment and prevention of bleeding in patients with haemophilia A. New information on authorised medicines. ⢠Feraccru (ferr
Jan 26, 2017 - is an antiparasitic medicine that treats the Varroa mite infestation in honey-bee colonies, which is considered to be the most significant parasitic ...
Treatment of cystine crystal deposits in the eye. New information on authorised medicines. Lucentis (ranibizumab) - change in indication. Treatment of visual ...
The new EudraVigilance system and the electronic reporting of individual case ... the ISO/ICH E2B(R3) format: hands-on training course - October 2017 ... granted a conditional marketing authorisation on the basis of less complete clinical data ...
4 days ago - EMA/CAT/426129/2018. Page 2/17. Table of contents. 1. Introduction. 5. 1.1. Welcome and declarations of interest of members, alternates and ...
Apr 10, 2017 - lifecycle. 2. Pharmacovigilance processes. 3. EU Network projects on .... 2016, it was clear that, while the service was improving, there was still ...
Sep 8, 2016 - 3-year report on Pharmacovigilance activities. Helen Lee, European Commission. â¢. Scanning the horizon for 2016 â 2018. Peter Arlett, EMA.
PCWP and HCPWP joint meeting - Sept 2016 - meeting documents. ⢠Workshop on identifying opportunities for 'big data' in medicines development and ...
Used for the management of hypovolaemia (low blood volume) caused by acute (sudden) blood loss .... EMA's Business Continuity Plan for Brexit published.
On arriving for your meeting at 30 Churchill Place, please report to reception where you will be issued with an access pass. This pass will allow you to enter our industry lounge, which you are welcome to utilise during your visit. The industry loung
RSS feeds you need one of the following: a modern web browser; a web-based news reader or a ... Withdrawal of applications for new medicines .... fifth annual regulatory conference on optimising the development of advanced therapies to.
Jan 26, 2017 - is an antiparasitic medicine that treats the Varroa mite infestation in honey-bee colonies, which is considered to be the most significant parasitic ...
RSS feeds you need one of the following: a modern web browser; a web-based news reader or a desktop news reader. For a list of RSS readers please refer to ...
Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc.
Jun 18, 2018 - 27. 7.8.1. List of all applications submitted/expected and the COMP coordinatorship distribution of .... 5,10-dihydrodibenzo[b,e][1,4] diazepin-11-one, EMA/OD/031/10 Glutathione-pegylated ...... Abbreviations / Acronyms.
Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc.
European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged. 13 September 2017. EMA/727763/2017. Human Medicines Evaluation Division. List of nationally authorised medicinal products. Active substance(s): dexlansop